KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares Outstanding
Ratios

AbCellera Biologics (ABCL) Depreciation Expense (2022 - 2026)

AbCellera Biologics filings provide 5 years of Depreciation Expense readings, the most recent being $5.9 million for Q1 2026.

  • Quarterly Depreciation Expense rose 33.82% to $5.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $19.8 million through Mar 2026, up 45.14% year-over-year, with the annual reading at $18.4 million for FY2025, 47.2% up from the prior year.
  • Depreciation Expense hit $5.9 million in Q1 2026 for AbCellera Biologics, up from $5.1 million in the prior quarter.
  • Across five years, Depreciation Expense topped out at $5.9 million in Q1 2026 and bottomed at $1.4 million in Q1 2022.
  • Average Depreciation Expense over 5 years is $3.4 million, with a median of $3.2 million recorded in 2024.
  • The largest annual shift saw Depreciation Expense tumbled 47.45% in 2024 before it surged 149.3% in 2025.
  • AbCellera Biologics' Depreciation Expense stood at $2.7 million in 2022, then skyrocketed by 43.23% to $3.9 million in 2023, then tumbled by 47.45% to $2.1 million in 2024, then surged by 149.3% to $5.1 million in 2025, then rose by 14.72% to $5.9 million in 2026.
  • Per Business Quant, the three most recent readings for ABCL's Depreciation Expense are $5.9 million (Q1 2026), $5.1 million (Q4 2025), and $4.3 million (Q3 2025).